Ratings Thermo Fisher Scientific Inc. Wiener Boerse

Equities

TMOF

US8835561023

End-of-day quote Wiener Boerse Other stock markets 03:30:00 29/05/2024 am IST			5-day change	1st Jan Change
524.6 ^EUR	+0.06%		-2.47%	+8.84%

31/05	Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation	CI
24/05	Declaration of Voting Results by Thermo Fisher Scientific Inc	CI

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Over the past four months, analysts' average price target has been revised upwards significantly.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company is in debt and has limited leeway for investment
With an expected P/E ratio at 35.67 and 30.59 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
THERMO FISHER SCIENTIFIC INC.	+8.84%	215B	-
DANAHER CORPORATION	+11.01%	187B	B-
INTUITIVE SURGICAL, INC.	+19.20%	143B	B-
BOSTON SCIENTIFIC CORPORATION	+30.79%	110B	A-
SIEMENS HEALTHINEERS AG	+1.48%	64.68B	A-
EDWARDS LIFESCIENCES CORPORATION	+13.95%	52.96B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.16%	49.84B	B+
AGILENT TECHNOLOGIES, INC.	-6.20%	38.32B	A
GE HEALTHCARE TECHNOLOGIES INC.	+0.91%	35.86B	-
RESMED, INC.	+19.95%	30.75B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes